Cargando…
Adjuvant endocrine therapy for premenopausal women with breast cancer: Patient adherence and physician prescribing practices in Mexico
BACKGROUND: In resource-constrained settings, data regarding breast cancer patients' adherence to endocrine therapy (ET) and physicians’ prescribing practices is limited. This study aims to decrease this knowledge gap in a real-world clinical practice. METHODS: Premenopausal women with stage 0-...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8192863/ https://www.ncbi.nlm.nih.gov/pubmed/34116366 http://dx.doi.org/10.1016/j.breast.2021.05.013 |
_version_ | 1783706126901051392 |
---|---|
author | Villarreal-Garza, Cynthia Mesa-Chavez, Fernanda Ferrigno, Ana S. De la Garza-Ramos, Cynthia Fonseca, Alan Villanueva-Tamez, Karen Campos-Salgado, Jose Y. Cruz-Ramos, Marlid Rodriguez-Gomez, David O. Ruiz-Cruz, Sandy Cabrera-Galeana, Paula |
author_facet | Villarreal-Garza, Cynthia Mesa-Chavez, Fernanda Ferrigno, Ana S. De la Garza-Ramos, Cynthia Fonseca, Alan Villanueva-Tamez, Karen Campos-Salgado, Jose Y. Cruz-Ramos, Marlid Rodriguez-Gomez, David O. Ruiz-Cruz, Sandy Cabrera-Galeana, Paula |
author_sort | Villarreal-Garza, Cynthia |
collection | PubMed |
description | BACKGROUND: In resource-constrained settings, data regarding breast cancer patients' adherence to endocrine therapy (ET) and physicians’ prescribing practices is limited. This study aims to decrease this knowledge gap in a real-world clinical practice. METHODS: Premenopausal women with stage 0-III hormone-sensitive breast cancer and receiving adjuvant ET during the past 1–5 years were identified in three Mexican referral centers. Participants' self-reported ET compliance, clinicopathologic characteristics, ET-related knowledge and beliefs, experienced adverse effects, social support, and patient-physician relationships were evaluated. Physician ET prescribing practices were compared with the gold standard according to international and national guidelines to assess clinicians’ adherence to standard-of-care prescription. RESULTS: In total, 95/132 (72%) and 35/132 (27%) participants reported complete and acceptable adherence, respectively. Incomplete adherence was mainly attributed to forgetfulness, adverse effects, and unwillingness to take ET. Being employed/studying (p = 0.042), worrying about long-term ET use (p = 0.031), and experiencing >7 ET-related symptoms (p = 0.018) were associated with incomplete adherence. Guideline-endorsed regimens were prescribed in 84/132 (64%) patients, while the rest should have undergone ovarian function suppression (OFS) but instead received tamoxifen monotherapy. CONCLUSIONS: Premenopausal Mexican women self-report remarkably high rates of adequate ET adherence. However, a considerable proportion misses ≥1 doses/month, usually because of forgetfulness. Notably, only 64% receive standard-of-care ET due to suboptimal prescription of OFS. Interventions that remind patients to take their ET, refine physicians’ knowledge on the importance of OFS in high-risk patients, and increase access to OFS could prove pivotal to enhance optimal ET implementation and adherence, which could translate into improved patient outcomes. |
format | Online Article Text |
id | pubmed-8192863 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Elsevier |
record_format | MEDLINE/PubMed |
spelling | pubmed-81928632021-06-17 Adjuvant endocrine therapy for premenopausal women with breast cancer: Patient adherence and physician prescribing practices in Mexico Villarreal-Garza, Cynthia Mesa-Chavez, Fernanda Ferrigno, Ana S. De la Garza-Ramos, Cynthia Fonseca, Alan Villanueva-Tamez, Karen Campos-Salgado, Jose Y. Cruz-Ramos, Marlid Rodriguez-Gomez, David O. Ruiz-Cruz, Sandy Cabrera-Galeana, Paula Breast Original Article BACKGROUND: In resource-constrained settings, data regarding breast cancer patients' adherence to endocrine therapy (ET) and physicians’ prescribing practices is limited. This study aims to decrease this knowledge gap in a real-world clinical practice. METHODS: Premenopausal women with stage 0-III hormone-sensitive breast cancer and receiving adjuvant ET during the past 1–5 years were identified in three Mexican referral centers. Participants' self-reported ET compliance, clinicopathologic characteristics, ET-related knowledge and beliefs, experienced adverse effects, social support, and patient-physician relationships were evaluated. Physician ET prescribing practices were compared with the gold standard according to international and national guidelines to assess clinicians’ adherence to standard-of-care prescription. RESULTS: In total, 95/132 (72%) and 35/132 (27%) participants reported complete and acceptable adherence, respectively. Incomplete adherence was mainly attributed to forgetfulness, adverse effects, and unwillingness to take ET. Being employed/studying (p = 0.042), worrying about long-term ET use (p = 0.031), and experiencing >7 ET-related symptoms (p = 0.018) were associated with incomplete adherence. Guideline-endorsed regimens were prescribed in 84/132 (64%) patients, while the rest should have undergone ovarian function suppression (OFS) but instead received tamoxifen monotherapy. CONCLUSIONS: Premenopausal Mexican women self-report remarkably high rates of adequate ET adherence. However, a considerable proportion misses ≥1 doses/month, usually because of forgetfulness. Notably, only 64% receive standard-of-care ET due to suboptimal prescription of OFS. Interventions that remind patients to take their ET, refine physicians’ knowledge on the importance of OFS in high-risk patients, and increase access to OFS could prove pivotal to enhance optimal ET implementation and adherence, which could translate into improved patient outcomes. Elsevier 2021-06-01 /pmc/articles/PMC8192863/ /pubmed/34116366 http://dx.doi.org/10.1016/j.breast.2021.05.013 Text en © 2021 The Authors. Published by Elsevier Ltd. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
spellingShingle | Original Article Villarreal-Garza, Cynthia Mesa-Chavez, Fernanda Ferrigno, Ana S. De la Garza-Ramos, Cynthia Fonseca, Alan Villanueva-Tamez, Karen Campos-Salgado, Jose Y. Cruz-Ramos, Marlid Rodriguez-Gomez, David O. Ruiz-Cruz, Sandy Cabrera-Galeana, Paula Adjuvant endocrine therapy for premenopausal women with breast cancer: Patient adherence and physician prescribing practices in Mexico |
title | Adjuvant endocrine therapy for premenopausal women with breast cancer: Patient adherence and physician prescribing practices in Mexico |
title_full | Adjuvant endocrine therapy for premenopausal women with breast cancer: Patient adherence and physician prescribing practices in Mexico |
title_fullStr | Adjuvant endocrine therapy for premenopausal women with breast cancer: Patient adherence and physician prescribing practices in Mexico |
title_full_unstemmed | Adjuvant endocrine therapy for premenopausal women with breast cancer: Patient adherence and physician prescribing practices in Mexico |
title_short | Adjuvant endocrine therapy for premenopausal women with breast cancer: Patient adherence and physician prescribing practices in Mexico |
title_sort | adjuvant endocrine therapy for premenopausal women with breast cancer: patient adherence and physician prescribing practices in mexico |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8192863/ https://www.ncbi.nlm.nih.gov/pubmed/34116366 http://dx.doi.org/10.1016/j.breast.2021.05.013 |
work_keys_str_mv | AT villarrealgarzacynthia adjuvantendocrinetherapyforpremenopausalwomenwithbreastcancerpatientadherenceandphysicianprescribingpracticesinmexico AT mesachavezfernanda adjuvantendocrinetherapyforpremenopausalwomenwithbreastcancerpatientadherenceandphysicianprescribingpracticesinmexico AT ferrignoanas adjuvantendocrinetherapyforpremenopausalwomenwithbreastcancerpatientadherenceandphysicianprescribingpracticesinmexico AT delagarzaramoscynthia adjuvantendocrinetherapyforpremenopausalwomenwithbreastcancerpatientadherenceandphysicianprescribingpracticesinmexico AT fonsecaalan adjuvantendocrinetherapyforpremenopausalwomenwithbreastcancerpatientadherenceandphysicianprescribingpracticesinmexico AT villanuevatamezkaren adjuvantendocrinetherapyforpremenopausalwomenwithbreastcancerpatientadherenceandphysicianprescribingpracticesinmexico AT campossalgadojosey adjuvantendocrinetherapyforpremenopausalwomenwithbreastcancerpatientadherenceandphysicianprescribingpracticesinmexico AT cruzramosmarlid adjuvantendocrinetherapyforpremenopausalwomenwithbreastcancerpatientadherenceandphysicianprescribingpracticesinmexico AT rodriguezgomezdavido adjuvantendocrinetherapyforpremenopausalwomenwithbreastcancerpatientadherenceandphysicianprescribingpracticesinmexico AT ruizcruzsandy adjuvantendocrinetherapyforpremenopausalwomenwithbreastcancerpatientadherenceandphysicianprescribingpracticesinmexico AT cabreragaleanapaula adjuvantendocrinetherapyforpremenopausalwomenwithbreastcancerpatientadherenceandphysicianprescribingpracticesinmexico |